Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
$312.32
3.611.17%
At close: -
$312.32
0.000.00%
After Hours: 4:00 PM EDT
Comments
Loading...
Alnylam Pharmaceuticals Analyst Ratings and Price Targets | NASDAQ:ALNY | Benzinga
Alnylam Pharmaceuticals Inc has a consensus price target of $317.42 based on the ratings of 27 analysts. The high is $500 issued by HC Wainwright & Co. on April 2, 2025. The low is $159 issued by Leerink Partners on June 25, 2024. The 3 most-recent analyst ratings were released by JP Morgan, UBS, and Chardan Capital on June 12, 2025, May 2, 2025, and May 2, 2025, respectively. With an average price target of $337.33 between JP Morgan, UBS, and Chardan Capital, there's an implied 8.01% upside for Alnylam Pharmaceuticals Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
JP Morgan
UBS
Chardan Capital
Morgan Stanley
Needham
1calculated from analyst ratings
Analyst Ratings for Alnylam Pharmaceuticals
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 06/12/2025 | Buy Now | 8.22% | JP Morgan | Jessica Fye67% | $330 → $338 | Maintains | Overweight | Get Alert |
| 05/02/2025 | Buy Now | 11.74% | UBS | Esther Rajavelu35% | $331 → $349 | Maintains | Buy | Get Alert |
| 05/02/2025 | Buy Now | 4.06% | Chardan Capital | Keay Nakae56% | $300 → $325 | Maintains | Buy | Get Alert |
| 04/11/2025 | Buy Now | -14.19% | Morgan Stanley | Michael Ulz66% | $284 → $268 | Maintains | Equal-Weight | Get Alert |
| 04/09/2025 | Buy Now | 2.46% | Needham | Joseph Stringer61% | $320 → $320 | Reiterates | Buy → Buy | Get Alert |
| 04/02/2025 | Buy Now | 60.09% | HC Wainwright & Co. | Patrick Trucchio50% | $500 → $500 | Reiterates | Buy → Buy | Get Alert |
| 03/31/2025 | Buy Now | 9.5% | Scotiabank | Greg Harrison48% | $338 → $342 | Maintains | Sector Outperform | Get Alert |
| 03/31/2025 | Buy Now | 13.03% | Redburn Atlantic | Joshua Smith 66% | → $353 | Initiates | → Buy | Get Alert |
| 03/31/2025 | Buy Now | 10.46% | Stifel | Paul Matteis44% | $300 → $345 | Maintains | Buy | Get Alert |
| 03/24/2025 | Buy Now | 5.02% | JP Morgan | Jessica Fye67% | $280 → $328 | Upgrade | Neutral → Overweight | Get Alert |
| 03/21/2025 | Buy Now | 12.38% | Citigroup | David Lebovitz65% | $338 → $351 | Maintains | Buy | Get Alert |
| 03/21/2025 | Buy Now | 24.87% | Canaccord Genuity | Whitney Ijem57% | $385 → $390 | Maintains | Buy | Get Alert |
| 03/21/2025 | Buy Now | 5.66% | RBC Capital | Luca Issi44% | $310 → $330 | Maintains | Outperform | Get Alert |
| 03/21/2025 | Buy Now | 8.22% | Scotiabank | Greg Harrison48% | $300 → $338 | Maintains | Sector Outperform | Get Alert |
| 03/21/2025 | Buy Now | -8.11% | Wells Fargo | Tiago Fauth47% | $275 → $287 | Maintains | Equal-Weight | Get Alert |
| 03/21/2025 | Buy Now | 4.06% | B of A Securities | Tazeen Ahmad56% | $302 → $325 | Maintains | Buy | Get Alert |
| 03/21/2025 | Buy Now | -3.94% | Chardan Capital | Keay Nakae56% | $300 → $300 | Maintains | Buy | Get Alert |
| 03/21/2025 | Buy Now | 2.46% | Needham | Joseph Stringer61% | $320 → $320 | Reiterates | Buy → Buy | Get Alert |
| 03/11/2025 | Buy Now | -10.35% | JP Morgan | Jessica Fye67% | $272 → $280 | Maintains | Neutral | Get Alert |
| 02/26/2025 | Buy Now | -0.74% | RBC Capital | Luca Issi44% | $310 → $310 | Reiterates | Outperform → Outperform | Get Alert |
| 02/26/2025 | Buy Now | -3.94% | Chardan Capital | Keay Nakae56% | $300 → $300 | Maintains | Buy | Get Alert |
| 02/26/2025 | Buy Now | 2.46% | Needham | Joseph Stringer61% | $320 → $320 | Reiterates | Buy → Buy | Get Alert |
| 02/25/2025 | Buy Now | 60.09% | HC Wainwright & Co. | Patrick Trucchio50% | $400 → $500 | Reiterates | Buy → Buy | Get Alert |
| 02/24/2025 | Buy Now | 60.09% | HC Wainwright & Co. | Patrick Trucchio50% | $400 → $500 | Maintains | Buy | Get Alert |
| 02/18/2025 | Buy Now | 23.27% | Canaccord Genuity | Whitney Ijem57% | $384 → $385 | Maintains | Buy | Get Alert |
| 02/14/2025 | Buy Now | -3.94% | Scotiabank | Greg Harrison48% | $310 → $300 | Maintains | Sector Outperform | Get Alert |
| 02/14/2025 | Buy Now | -9.07% | Morgan Stanley | Michael Ulz66% | $275 → $284 | Maintains | Equal-Weight | Get Alert |
| 02/14/2025 | Buy Now | 2.46% | Needham | Joseph Stringer61% | $320 → $320 | Reiterates | Buy → Buy | Get Alert |
| 02/11/2025 | Buy Now | -3.94% | RBC Capital | Luca Issi44% | $300 → $300 | Reiterates | Outperform → Outperform | Get Alert |
| 01/21/2025 | Buy Now | -3.94% | RBC Capital | Luca Issi44% | $300 → $300 | Reiterates | Outperform → Outperform | Get Alert |
| 01/13/2025 | Buy Now | 28.07% | HC Wainwright & Co. | Patrick Trucchio50% | $400 → $400 | Reiterates | Buy → Buy | Get Alert |
| 01/13/2025 | Buy Now | 2.46% | Needham | Joseph Stringer61% | $320 → $320 | Reiterates | Buy → Buy | Get Alert |
| 01/07/2025 | Buy Now | -0.74% | Bernstein | William Pickering38% | $314 → $310 | Maintains | Outperform | Get Alert |
| 11/18/2024 | Buy Now | -5.23% | Piper Sandler | Edward Tenthoff52% | $296 → $296 | Reiterates | Overweight → Overweight | Get Alert |
| 11/18/2024 | Buy Now | 28.07% | HC Wainwright & Co. | Patrick Trucchio50% | $400 → $400 | Reiterates | Buy → Buy | Get Alert |
| 11/12/2024 | Buy Now | — | Wolfe Research | Andy Chen46% | — | Downgrade | Peer Perform → Underperform | Get Alert |
| 11/04/2024 | Buy Now | 28.07% | HC Wainwright & Co. | Patrick Trucchio50% | $400 → $400 | Reiterates | Buy → Buy | Get Alert |
| 11/01/2024 | Buy Now | -4.59% | Raymond James | Gary Nachman60% | $275 → $298 | Maintains | Outperform | Get Alert |
| 11/01/2024 | Buy Now | -3.94% | RBC Capital | Luca Issi44% | $300 → $300 | Reiterates | Outperform → Outperform | Get Alert |
| 11/01/2024 | Buy Now | -0.74% | Scotiabank | Greg Harrison48% | $305 → $310 | Maintains | Sector Outperform | Get Alert |
| 11/01/2024 | Buy Now | 5.34% | Barclays | Gena Wang51% | $295 → $329 | Maintains | Overweight | Get Alert |
| 11/01/2024 | Buy Now | 22.95% | Canaccord Genuity | Whitney Ijem57% | $366 → $384 | Maintains | Buy | Get Alert |
| 11/01/2024 | Buy Now | -3.94% | Chardan Capital | Keay Nakae56% | $300 → $300 | Maintains | Buy | Get Alert |
| 11/01/2024 | Buy Now | 2.46% | Needham | Joseph Stringer61% | $320 → $320 | Reiterates | Buy → Buy | Get Alert |
| 10/21/2024 | Buy Now | 18.79% | TD Cowen | Ritu Baral40% | $282 → $371 | Maintains | Buy | Get Alert |
| 10/18/2024 | Buy Now | 28.07% | HC Wainwright & Co. | Patrick Trucchio50% | $400 → $400 | Reiterates | Buy → Buy | Get Alert |
| 10/16/2024 | Buy Now | -2.34% | Scotiabank | Greg Harrison48% | → $305 | Initiates | → Sector Outperform | Get Alert |
| 10/14/2024 | Buy Now | 0.54% | B of A Securities | Tazeen Ahmad56% | $307 → $314 | Maintains | Buy | Get Alert |
| 10/11/2024 | Buy Now | -3.94% | Chardan Capital | Keay Nakae56% | $300 → $300 | Maintains | Buy | Get Alert |
| 10/11/2024 | Buy Now | -29.56% | Cantor Fitzgerald | Olivia Brayer53% | $220 → $220 | Reiterates | Neutral → Neutral | Get Alert |
| 10/10/2024 | Buy Now | -3.94% | RBC Capital | Luca Issi44% | $300 → $300 | Reiterates | Outperform → Outperform | Get Alert |
| 10/10/2024 | Buy Now | 2.46% | Needham | Joseph Stringer61% | $320 → $320 | Reiterates | Buy → Buy | Get Alert |
| 09/19/2024 | Buy Now | -3.94% | RBC Capital | Luca Issi44% | $300 → $300 | Reiterates | Outperform → Outperform | Get Alert |
| 09/09/2024 | Buy Now | -29.56% | Cantor Fitzgerald | Olivia Brayer53% | $220 → $220 | Reiterates | Neutral → Neutral | Get Alert |
| 09/04/2024 | Buy Now | -3.94% | RBC Capital | Luca Issi44% | $300 → $300 | Reiterates | Outperform → Outperform | Get Alert |
| 09/04/2024 | Buy Now | -1.7% | B of A Securities | Tazeen Ahmad56% | $295 → $307 | Maintains | Buy | Get Alert |
| 08/30/2024 | Buy Now | 28.07% | HC Wainwright & Co. | Patrick Trucchio50% | $400 → $400 | Reiterates | Buy → Buy | Get Alert |
| 08/26/2024 | Buy Now | -10.35% | JP Morgan | Jessica Fye67% | $248 → $280 | Maintains | Neutral | Get Alert |
| 08/20/2024 | Buy Now | 28.07% | HC Wainwright & Co. | Patrick Trucchio50% | $400 → $400 | Reiterates | Buy → Buy | Get Alert |
| 08/16/2024 | Buy Now | 18.47% | Goldman Sachs | Salveen Richter52% | $198 → $370 | Upgrade | Neutral → Buy | Get Alert |
| 08/02/2024 | Buy Now | -3.94% | RBC Capital | Luca Issi44% | $265 → $300 | Maintains | Outperform | Get Alert |
| 08/02/2024 | Buy Now | -25.4% | Wells Fargo | Tiago Fauth47% | $207 → $233 | Maintains | Equal-Weight | Get Alert |
| 08/02/2024 | Buy Now | -11.95% | Raymond James | Gary Nachman60% | $242 → $275 | Maintains | Outperform | Get Alert |
| 08/02/2024 | Buy Now | -36.6% | Goldman Sachs | Salveen Richter52% | $174 → $198 | Maintains | Neutral | Get Alert |
| 08/02/2024 | Buy Now | 9.5% | Citigroup | David Lebovitz65% | $291 → $342 | Maintains | Buy | Get Alert |
| 08/02/2024 | Buy Now | -5.55% | Barclays | Gena Wang51% | $291 → $295 | Maintains | Overweight | Get Alert |
| 08/02/2024 | Buy Now | 17.19% | Canaccord Genuity | Whitney Ijem57% | $357 → $366 | Maintains | Buy | Get Alert |
| 08/02/2024 | Buy Now | 2.46% | Needham | Joseph Stringer61% | $275 → $320 | Maintains | Buy | Get Alert |
| 07/22/2024 | Buy Now | -29.56% | Cantor Fitzgerald | Olivia Brayer53% | $150 → $220 | Maintains | Neutral | Get Alert |
| 07/12/2024 | Buy Now | -18.35% | Morgan Stanley | Michael Ulz66% | $250 → $255 | Maintains | Equal-Weight | Get Alert |
| 07/08/2024 | Buy Now | 14.31% | Canaccord Genuity | Whitney Ijem57% | $283 → $357 | Maintains | Buy | Get Alert |
| 07/03/2024 | Buy Now | -20.59% | JP Morgan | Jessica Fye67% | $160 → $248 | Maintains | Neutral | Get Alert |
| 07/01/2024 | Buy Now | -51.97% | Cantor Fitzgerald | Olivia Brayer53% | $150 → $150 | Reiterates | Neutral → Neutral | Get Alert |
| 06/28/2024 | Buy Now | -7.79% | UBS | Eliana Merle50% | $253 → $288 | Maintains | Buy | Get Alert |
| 06/27/2024 | Buy Now | -15.15% | RBC Capital | Luca Issi44% | $250 → $265 | Maintains | Outperform | Get Alert |
| 06/27/2024 | Buy Now | -5.55% | Stifel | Paul Matteis44% | $215 → $295 | Maintains | Buy | Get Alert |
| 06/25/2024 | Buy Now | -6.83% | Citigroup | David Lebovitz65% | $227 → $291 | Maintains | Buy | Get Alert |
| 06/25/2024 | Buy Now | -5.55% | B of A Securities | — | $248 → $295 | Maintains | Buy | Get Alert |
| 06/25/2024 | Buy Now | -49.09% | Leerink Partners | — | $138 → $159 | Maintains | Market Perform | Get Alert |
| 06/25/2024 | Buy Now | -9.71% | TD Cowen | Ritu Baral40% | $260 → $282 | Maintains | Buy | Get Alert |
| 06/25/2024 | Buy Now | -16.75% | Evercore ISI Group | Liisa Bayko70% | $210 → $260 | Maintains | Outperform | Get Alert |
| 06/25/2024 | Buy Now | -6.83% | Barclays | Gena Wang51% | $236 → $291 | Maintains | Overweight | Get Alert |
| 06/25/2024 | Buy Now | -19.95% | RBC Capital | Luca Issi44% | $235 → $250 | Maintains | Outperform | Get Alert |
| 06/25/2024 | Buy Now | -33.72% | Wells Fargo | Tiago Fauth47% | $161 → $207 | Maintains | Equal-Weight | Get Alert |
| 06/25/2024 | Buy Now | -19.95% | Morgan Stanley | Michael Ulz66% | $164 → $250 | Maintains | Equal-Weight | Get Alert |
| 06/24/2024 | Buy Now | -11.95% | Needham | Joseph Stringer61% | $200 → $275 | Maintains | Buy | Get Alert |
| 06/24/2024 | Buy Now | 28.07% | HC Wainwright & Co. | Patrick Trucchio50% | $400 → $400 | Reiterates | Buy → Buy | Get Alert |
| 06/24/2024 | Buy Now | -25.08% | BMO Capital | Kostas Biliouris34% | $234 → $234 | Maintains | Outperform | Get Alert |
| 06/21/2024 | Buy Now | -9.39% | Canaccord Genuity | Whitney Ijem57% | $283 → $283 | Maintains | Buy | Get Alert |
| 05/07/2024 | Buy Now | 28.07% | HC Wainwright & Co. | Patrick Trucchio50% | $395 → $400 | Maintains | Buy | Get Alert |
| 05/03/2024 | Buy Now | -27.96% | Chardan Capital | Keay Nakae56% | $225 → $225 | Maintains | Buy | Get Alert |
| 05/02/2024 | Buy Now | -35.96% | Needham | Joseph Stringer61% | $200 → $200 | Reiterates | Buy → Buy | Get Alert |
| 03/27/2024 | Buy Now | -25.08% | BMO Capital | Kostas Biliouris34% | $234 → $234 | Maintains | Outperform | Get Alert |
| 03/05/2024 | Buy Now | 26.47% | HC Wainwright & Co. | Patrick Trucchio50% | $395 → $395 | Reiterates | Buy → Buy | Get Alert |
| 02/23/2024 | Buy Now | -51.97% | Cantor Fitzgerald | Olivia Brayer53% | $165 → $150 | Maintains | Neutral | Get Alert |
| 02/21/2024 | Buy Now | -24.76% | RBC Capital | Luca Issi44% | $235 → $235 | Reiterates | Outperform → Outperform | Get Alert |
| 02/20/2024 | Buy Now | -24.76% | RBC Capital | Luca Issi44% | $235 → $235 | Reiterates | Outperform → Outperform | Get Alert |
| 02/20/2024 | Buy Now | -47.17% | Cantor Fitzgerald | Olivia Brayer53% | → $165 | Reiterates | Neutral → Neutral | Get Alert |
| 02/16/2024 | Buy Now | -24.76% | RBC Capital | Luca Issi44% | $235 → $235 | Reiterates | Outperform → Outperform | Get Alert |
| 02/16/2024 | Buy Now | -48.45% | Wells Fargo | Tiago Fauth47% | $171 → $161 | Maintains | Equal-Weight | Get Alert |
FAQ
What is the target price for Alnylam Pharmaceuticals (ALNY) stock?
The latest price target for Alnylam Pharmaceuticals (NASDAQ:ALNY) was reported by JP Morgan on June 12, 2025. The analyst firm set a price target for $338.00 expecting ALNY to rise to within 12 months (a possible 8.22% upside). 89 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Alnylam Pharmaceuticals (ALNY)?
The latest analyst rating for Alnylam Pharmaceuticals (NASDAQ:ALNY) was provided by JP Morgan, and Alnylam Pharmaceuticals maintained their overweight rating.
When was the last upgrade for Alnylam Pharmaceuticals (ALNY)?
The last upgrade for Alnylam Pharmaceuticals Inc happened on March 24, 2025 when JP Morgan raised their price target to $328. JP Morgan previously had a neutral for Alnylam Pharmaceuticals Inc.
When was the last downgrade for Alnylam Pharmaceuticals (ALNY)?
The last downgrade for Alnylam Pharmaceuticals Inc happened on November 12, 2024 when Wolfe Research changed their price target from N/A to N/A for Alnylam Pharmaceuticals Inc.
When is the next analyst rating going to be posted or updated for Alnylam Pharmaceuticals (ALNY)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Alnylam Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Alnylam Pharmaceuticals was filed on June 12, 2025 so you should expect the next rating to be made available sometime around June 12, 2026.
Is the Analyst Rating Alnylam Pharmaceuticals (ALNY) correct?
While ratings are subjective and will change, the latest Alnylam Pharmaceuticals (ALNY) rating was a maintained with a price target of $330.00 to $338.00. The current price Alnylam Pharmaceuticals (ALNY) is trading at is $312.32, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.
